Roche may have failed to buy out Illumina back in 2012, but now it’s trying to take up some of the gene sequencing specialist ...

AbbVie has struck a deal to buy Apogee Therapeutics for $10.9 b | AbbVie has struck a deal to buy Apogee Therapeutics for $10 ...

Five months after Corxel Pharmaceuticals reeled in hundreds of millions of dollars to support further development of its oral ...

The beleaguered genomic medicine biotech Sangamo has traveled a rough road lately, with recent years | Eli Lilly and Astellas ...

Exelixis’ next franchise in a drug, zanzalintinib, has hit a clinical setback, although at least two groups of analysts ...

When writing a blockbuster movie script, screenplay writers are sure to include all the essential elements of a hit | The ...

Despite its massive $10.5 billion size and 12-drug scope, Pfizer’s oncology deal with Innovent Biologics took less than five ...

Insillico Medicine and SK Biopharmaceuticals have teamed up on an AI-enabled search for drug candidates targeting neuroimmune ...

During her presentation, Moderna’s Das said the company proposed a “modified regulatory framework” during the FDA meeting.

Osanni launched three years ago with a $27 million series A and has kept purposefully quiet ever since, founder and CEO ...

Pfizer’s high-stakes bet on antibody-drug conjugates (ADCs) has hit a speed bump. | Pfizer announced Monday that sigvotatug ...

Omnipod maker Insulet has hired Divakar Ramakrishnan, Ph.D., as its new Chief Research and Development Officer. | Omnipod ...